Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 208 от 240

Active (not recruiting)

Supporting Tools and Cognitive Aids for BLS

Basic Life Support (Simulation)

Various studies have shown that rapid and correctly performed cardiopulmonary resuscitation (CPR) significantly increases the survival rate after cardiac arrest. Such a situation can affect anyone, anywhere and at any time, making it all the more important to master the basic skills and abilities of Basic Life Support (BLS). Thanks to constant technical progress, there are now numerous digital tools in the field of lay resuscitation. There are also feedback devices for CPR for laypersons, the use of which is currently the subject of scientific debate. In order to evaluate the influence of various tools on the quality of lay resuscitation, we are planning a prospective, randomized study in a parallel group design. This study is aimed at medical laypersons between the ages of 18 and 70 who have completed a BLS course (e.g. first aid course for driver\'s license) within the last 10 years. All participants are asked to take part in a mannequin-based simulation scenario in a public place. As part of this simulation scenario, the BLS algorithm is to be performed (recognizing respiratory-circulatory arrest, calling for help, performing chest compressions, organizing a defibrillator). After performing the 1-minute cardiac massage, the scenario is ended. We plan to randomize into 3 groups. Group 1 will receive paper-based information material on how to perform BLS correctly. Group 2 will receive a first aid app. Group 3 will receive a small medical device (CorPatch®), which gives direct feedback on the quality of chest compressions (e.g. frequency, depth), including an accompanying app for support. The time to blood flow (defined as the succession of 5 sufficient chest compressions in this study) will be evaluated as the primary outcome. Secondarily, resuscitation management will be evaluated using a validated BLS checklist, the time to critical actions (such as time to alert the emergency services), the quality of CPR, the cognitive load of the participants and the user-friendliness of the assigned aid.

Начало: 16.09.2024 Край: 31.12.2026 Възраст: 18–70 г.

Austria Medical University of Vienna NCT06601946

Active (not recruiting) Phase 2

A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction

Erectile Dysfunction

Erectile dysfunction (ED) is a common condition characterized by the inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It can significantly affect physical health, emotional well-being, and quality of life for both patients and their partners. Standard treatment options include medications such as phosphodiesterase type 5 inhibitors, vacuum devices, intracavernosal or transurethral therapies, and surgical implantation of penile prostheses. In recent years, low-intensity shock wave therapy has also been introduced as a treatment option. However, these approaches may have limitations in effectiveness, invasiveness, or long-term outcomes, highlighting the need for alternative therapies. Advances in regenerative medicine have introduced new potential treatment strategies, including the use of autologous mesenchymal stem cells derived from bone marrow or adipose tissue. These therapies aim to improve tissue repair and restore erectile function. Previous preclinical and clinical studies suggest that mesenchymal stem cell therapy may be safe and effective, but direct comparisons between different sources of stem cells remain limited. This prospective study aims to evaluate and compare the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells, adipose tissue-derived mesenchymal stromal cells, and platelet-rich plasma (PRP) therapy in patients with organic erectile dysfunction. A control group receiving standard conservative treatment, including low-intensity shock wave therapy, will also be included. The study will be conducted in a population of patients in Kazakhstan and will assess outcomes before and after treatment to determine improvements in erectile function and overall patient well-being. The results may help identify more effective and regenerative treatment approaches for patients with organic erectile dysfunction.

Начало: 09.09.2024 Край: 01.11.2026 Възраст: 18–70 г.

Kazakhstan National Scientific Medical Center, Kazakhstan NCT07544537

Active (not recruiting) Phase 3

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Начало: 09.09.2024 Край: 29.05.2028 Възраст: 18–99 г.

Argentina, Austria, Brazil +21 Amgen NCT06311721

Active (not recruiting) Phase 2/3

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed

HIV-1-Infection

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of lepetegravir and lenacapavir pacfosacil with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, BVY), to see if the combination of lepetegravir and lenacapavir pacfosacil is safe and if it works for treating human immunodeficiency virus type 1 (HIV-1) infection. This study has two phases: Phase 2 and Phase 3. The primary objectives of this study are: Phase 2: To evaluate the efficacy of switching to oral weekly lepetegravir in combination with lenacapavir pacfosacil versus continuing BVY in virologically suppressed people with HIV-1 (PWH) at Week 24. Phase 3: To evaluate the efficacy of switching to oral weekly lepetegravir /lenacapavir pacfosacil Fixed-dose combination (FDC) tablet regimen versus continuing BVY in virologically suppressed PWH at Week 48.

Начало: 20.08.2024 Край: 01.06.2029 Възраст: от 18 г.

Puerto Rico, United States Gilead Sciences NCT06544733

Active (not recruiting)

Physical Activity Centers Empowerment

Colorectal Neoplasms

This research study tests the feasibility of the Physical Activity Centers Empowerment (PACE) physical activity intervention for African American individuals diagnosed with colorectal cancer. Feasibility will be measured as intervention reach, effectiveness, adoption, implementation, and maintenance. Seventy-two subjects will be recruited to conduct a pilot two-group, randomized repeated measures study.

Начало: 14.08.2024 Край: 01.06.2026 Възраст: от 18 г.

United States UNC Lineberger Comprehensive Cancer Center NCT06411756

Active (not recruiting) Phase 1

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor Metastatic Solid Tumor Prostate Cancer Pancreas Cancer +3

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Начало: 13.08.2024 Край: 30.11.2027 Възраст: от 18 г.

Spain, United Kingdom, United States MOMA Therapeutics NCT06545942

Active (not recruiting) Phase 1

COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

SARS-CoV-2 Infection

A phase 1, dose-finding open label clinical infection, safety and viral detection optimization in healthy volunteers immunologically experienced against SARS-CoV-2.

Начало: 08.08.2024 Край: 31.10.2028 Възраст: 18–40 г.

United Kingdom University of Oxford NCT06478420

Active (not recruiting) Phase 2

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Advanced Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy. The names of the study drugs involved in this study are: * AGEN1423 * Botensilimab Participants will receive study treatment for about 2 years and will be followed for 1 year after.

Начало: 08.08.2024 Край: 01.04.2027 Възраст: от 18 г.

United States Bruno Bockorny NCT05632328

Active (not recruiting) Phase 3

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Small Cell Lung Cancer

This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal Antibodies and platinum-based chemotherapy.

Начало: 07.08.2024 Край: 01.12.2026 Възраст: от 18 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT06500026

Active (not recruiting) Phase 2

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

Metastatic Renal Cell Carcinoma

To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.

Начало: 07.08.2024 Край: 01.10.2026 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT06284564

Active (not recruiting)

A Study of Oral Kavalactones Effect on Nurses

Stress

This research study is being done to assess the impact of taking Kava extract (Piper methysticum), a dietary supplement on cortisol in a healthy nursing population.

Начало: 05.08.2024 Край: 30.06.2026 Възраст: от 18 г.

United States Mayo Clinic NCT06177535

Active (not recruiting) Phase 2

Iptacopan in Patients With ANCA Associated Vasculitis

Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis

The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.

Начало: 05.08.2024 Край: 30.12.2026 Възраст: 18–100 г. Treatment

Argentina, Australia, Austria +12 Novartis Pharmaceuticals NCT06388941

Active (not recruiting)

HOPE at Heart (HOPE) of Donor Hearts After Circulatory Death (DCD) Using the XVIVO Heart Assist Transport System.

Heart Failure

The purpose of the clinical investigation is to support the use of direct procurement of donor hearts in donation after circulatory death followed by hypothermic oxygenated perfusion using the XVIVO Heart Assist Transport System. Thereby increasing the utilization of DCD donor hearts in donation after circulatory death. The primary objective is to evaluate patient survival after direct procurement and hypothermic oxygenated machine perfusion of DCD donor hearts using the XVIVO Heart Assist Transport System. The secondary objectives are to evaluate patient outcomes and graft function post-transplant.

Начало: 03.08.2024 Край: 01.06.2026 Възраст: от 18 г.

Belgium XVIVO Perfusion NCT06485596

Active (not recruiting) Phase 3

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Respiratory Syncytial Virus Infections

The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose of the RSVPreF3 OA vaccine and collect additional safety information.

Начало: 01.08.2024 Край: 30.09.2026 Възраст: от 60 г. Prevention

Australia, Belgium, Canada +14 GlaxoSmithKline NCT06534892

Active (not recruiting)

Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC

Hepatocellular Carcinoma

This study is a single-arm, open-label trial to clarify the safety and efficacy of the combined treatment of lenvatinib and VIC-1911 in patients with advanced liver cancer.

Начало: 01.08.2024 Край: 31.07.2026 Възраст: 18–75 г.

China RenJi Hospital NCT06519721

Active (not recruiting) Phase 2

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm

This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Panitumumab is in a class of medications called monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. Giving combination panitumumab and sotorasib may kill more tumor cells in patients with advanced solid tumors with KRAS G12C mutation.

Начало: 01.08.2024 Край: 31.12.2028 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT05638295

Active (not recruiting) Phase 2

A Study to Evaluate Solriktug in Adult Participants With Asthma

Asthma

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Начало: 26.07.2024 Край: 30.09.2026 Възраст: 18–75 г.

United States Uniquity One (UNI) NCT06496607

Active (not recruiting)

Servo-n HFOV Study: Safety and Performance in Neonates and Infants

Elective HFOV for Respiratory Failure in Neonates/Infants Rescue HFOV in Neonates and/Infants With Refractory Respiratory Failure Under Conventional Therapy

The purpose of this study is to evaluate the safety and performance of High-Frequency Oscillatory Ventilation (HFOV) modes of the Servo-n ventilator in neonates and infants, by using a prospective, observational, single-arm (i.e., non-controlled) and multi-center Post-Market Follow-up (PMCF) study design. HFOV treatment will be evaluated by assessing ventilation and oxygenation variables, and safety will be evaluated by documentation of device related adverse events.

Начало: 15.07.2024 Край: 30.06.2026

France, Poland, Switzerland Maquet Critical Care AB NCT06114992

Active (not recruiting)

Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control

Myopia

The purpose of the study is to investigate the combination effect of optical defocus and low dose atropine on myopia control in schoolchildren.

Начало: 12.07.2024 Край: 31.01.2027 Възраст: 7–12 г.

Hong Kong The Hong Kong Polytechnic University NCT06358755

Active (not recruiting)

Evaluation of Improved Onboard Patient Imaging

Head and Neck Cancer Breast Cancer Upper Gastrointestinal Cancer Lung Cancer +1

The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.

Начало: 10.07.2024 Край: 01.12.2026 Възраст: от 18 г.

United States Varian, a Siemens Healthineers Company NCT06187103

1 … 206 207 208 209 210 … 240